Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC) for RCC.
|NCPE Assessment Process||Completed|
|Rapid review commissioned||28/11/2018|
|Rapid review completed||11/12/2018|
|Rapid Review outcome||Full pharmacoeconomic assessment is recommended|
|HTA commissioned by the HSE||19/12/2018|
|Pre-submission consultation with Applicant||28/01/2019|
|Submission received from Applicant||01/04/2019|
|NCPE assessment commenced||17/07/2019|
|Preliminary review sent to Applicant||23/09/2019|
|NCPE assessment re-commenced||21/10/2019|
|Factual accuracy sent to Applicant||28/11/2019|
|NCPE assessment re-commenced||06/12/2019|
|NCPE assessment completed||07/01/2020|
|NCPE assessment outcome||The NCPE recommends that nivolumab in combination with ipilimumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.